PharmTech spoke with Tara Dougal, event director for pharma at Informa Markets, about trends impacting the pharmaceutical industry and how CPHI Milan is addressing these areas this year.
News|Articles|March 17, 2020
BPSA Summit Postponed for Fall 2020 After COVID-19 Outbreak
Author(s)Pharmaceutical Technology Editors
The decision comes after a state-of-emergency was declared in Washington, DC, due to the ongoing outbreak of COVID-19.
Advertisement
On March 16, 2020, Kevin Ott, director of the Bio-Process Systems Alliance (BPSA) announced in an email to BPSA members and contacts that the BPSA Summit scheduled for July 15–17, 2020 in Washington, DC, will be postponed for a later date in fall 2020. The decision comes after a state-of-emergency was declared in Washington, DC, due to the ongoing outbreak of COVID-19.
“The decision to postpone our 10th Anniversary BPSA Summit was not an easy one to make, but we believe this is the proper course of action given the uncontrollable externalities we all face at the moment,” Ott said in the email. “We believe this to be a prudent business decision, and it is unanimously supported by the BPSA [e]xecutive [c]ommittee.”
Source:
Advertisement
Related to this article
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
FDA opens applications for its Expedited IND Pilot, pairing sponsors with qualified research institutions to test rolling CMC review ahead of first-in-human trials.
2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
Karthik Iyer, Eli Lilly, details an AI system linking GMP findings, audits, and deviations for cited, inspection-ready regulatory intelligence.
Advertisement
Advertisement